Your browser doesn't support javascript.
loading
Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer ; (12): 703-711, 2018.
Article in Chinese | WPRIM | ID: wpr-772376
ABSTRACT
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work.
.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Pharmacology / Receptor Protein-Tyrosine Kinases / Carcinoma, Non-Small-Cell Lung / Drug Resistance, Neoplasm / Therapeutic Uses / Protein Kinase Inhibitors / Drug Therapy / Gene Fusion / Anaplastic Lymphoma Kinase / Genetics Limits: Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2018 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Pharmacology / Receptor Protein-Tyrosine Kinases / Carcinoma, Non-Small-Cell Lung / Drug Resistance, Neoplasm / Therapeutic Uses / Protein Kinase Inhibitors / Drug Therapy / Gene Fusion / Anaplastic Lymphoma Kinase / Genetics Limits: Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2018 Type: Article